AbolerIS Pharma is developing a first-in-class monoclonal antibody that induces immune tolerance to treat chronic autoimmune and inflammatory diseases, including transplant rejection and graft-versus-host disease. Their approach aims to restore immune system balance while preserving beneficial immune responses, addressing the challenges of managing these complex conditions.

AdipoPharma SAS is developing a therapeutic peptide, PATAS, that targets adipocyte cells to restore healthy lipid biosynthesis and reduce harmful lipids like ceramides, which contribute to insulin resistance and type 2 diabetes. This approach aims to improve metabolic health by addressing the underlying lipid management issues associated with these conditions, with clinical trials set to begin in 2025.

DeuterOncology is developing DO-2, a deuterated MET kinase inhibitor designed to enhance the efficacy and tolerability of targeted therapies for MET-driven lung cancer. This compound aims to reduce metabolic liabilities and improve drug exposure at lower doses, addressing the limitations of existing MET inhibitors in oncology treatments.

The startup develops tetratricopeptide repeat (PPR) proteins for precise genome editing of DNA and RNA sequences. This technology enables researchers to enhance agricultural productivity and advance pharmaceutical drug development through targeted genetic modifications.

Epic Therapeutics, Inc. is developing RNA-based therapeutics that target METTL3 methyltransferase, a key enzyme linked to m6A modification, to inhibit tumor growth in acute myeloid leukemia and solid tumors. Their lead candidate, EP102, has demonstrated significant in vivo efficacy, addressing the critical need for effective cancer treatments amid the slow approval of new therapies.

Neuvasq Biotechnologies develops therapies that restore blood-brain barrier function and enhance neurovascular integrity for patients with severe neurological disorders, including stroke, epilepsy, and Alzheimer's disease. Their platform targets the repair of central nervous system barriers, addressing critical challenges in treating acute and chronic neurological conditions.

Santero Therapeutics develops novel therapeutics targeting antibiotic-resistant pathogens through unique mechanisms of action derived from over a decade of foundational research. The company addresses the critical challenge of rising antibiotic resistance, which renders previously treatable bacterial infections increasingly difficult to manage.

Tensegrity Pharma develops a novel drug platform that addresses bottlenecks in the drug development process by utilizing a unique structural approach inspired by tensegrity principles. This method enhances collaboration among a specialized team of professionals, transforming underutilized drug candidates into valuable therapeutic options for patients.